Rimegepant, an oral CGRP receptor antagonist, demonstrates high affinity, rapid action, and sustained efficacy for acute and preventive migraine.

Migraine is a debilitating neurological disorder imposing significant burden. Conventional acute and preventive treatments often face challenges like contraindications, delayed efficacy, and adverse drug reactions. Specifically, some vasoconstrictive agents used for acute relief carry cardiovascular risks, limiting their use. The calcitonin gene-related peptide (CGRP) pathway has emerged as a key target in migraine pathophysiology. Developing an orally available, safe, and effective CGRP antagonist that can address both acute and preventive needs without cardiovascular concerns represents a significant therapeutic advancement.

This paper reviewed and synthesized data from nonclinical studies, Phase 1 studies in healthy Japanese adults, and multiple clinical trials to characterize the pharmacological profile and clinical outcomes of Rimegepant (Nurtec® ODT). The analysis focused on its CGRP receptor affinity, cardiovascular safety, pharmacokinetic properties (absorption, half-life), drug-drug interactions, and efficacy for both acute and preventive migraine treatment, including monthly migraine days reduction with specific dosing regimens.

Nonclinical studies confirmed Rimegepant's high affinity for the CGRP receptor without inducing vasoconstriction in coronary or intracranial arteries. Consistent with this, clinical studies showed no signals suggestive of cardiovascular risk, differentiating it from triptans. Phase 1 studies in healthy Japanese adults demonstrated Rimegepant's rapid absorption, supporting a rapid onset of action for acute treatment, and a relatively long half-life of 10 hours, supporting sustained efficacy. Drug-drug interaction studies confirmed that co-administration with triptans is possible due to a lack of clinically meaningful blood pressure elevation or pharmacokinetic interactions. Multiple clinical trials confirmed its efficacy and safety for acute treatment. > Every other day (EOD) dosing of Rimegepant significantly reduced monthly migraine days for prevention, offering a flexible oral option compared to injectable CGRP monoclonal antibodies.